Published Date : Oct 09, 2018
Novel technology enables detection of early-stage lung cancer when surgical cure still is possible
Non-small-cell lung carcinoma is a kind of cancer that often turns out to be fatal owing to the fact that early diagnosis is not possible in most cases and cases often advance to a stage when surgical intervention does not remain a possibility. So as to improve the situation, researchers have been seeking ways of detecting the condition earlier in terms of development.
One such research project has led to the development of a new technology called electric field-induced release and measurement. The technology is both immensely specific and sensitive when it comes to the detection of two epidermal growth factor receptor mutations that are often linked with lung cancer in the blood of patients suffering from the early stages of non-small-cell lung sarcoma. The technology offers a highly reliable testing platform that is also relatively inexpensive.
Despite the vast developments observed in the field of chemotherapy, the survival rate for patients with advanced stages of NSCLC is extremely low. If the condition is diagnosed in early stages, when surgical cure and resection are possible, the mortality rate of this condition can be significantly brought down. As such, the new technology brings forth an interesting development in the area, providing a noninvasive biopsy that depends on an economical saliva or blood test for effective diagnosis. The new technology can also prove to be beneficial when it comes to monitoring the course and impact of treatment and detecting recurrence of the condition in patients that have been diagnosed with it.
However, the researchers clarify that the technology does not give direct evidence that the presence of EGFR mutations in the plasma of the patient will mean that the patient is suffering from the cancer. Further work needs to be done in the area to understand whether EGFR mutation is indeed a prediction and currently, the treatment may be able to guide the selection of treatment plans in some patients.